Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/17/15Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer
PHILADELPHIA and OXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 p... 
Printer Friendly Version
12/03/15Adaptimmune Wins Scrip Award for Financing Deal of the Year
PHILADELPHIA and OXFORD, United Kingdom, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has won the Financing Deal of the Year Award at the 2015 Scrip awards. The global industry award recognizes Adaptimmune’s achievements in the exciting and competitive immunotherapy space. In September 2014, Adaptimmune secured $104 million in a Series A round led by New Enterprise... 
Printer Friendly Version
12/01/15Adaptimmune and Universal Cells Announce Collaboration to Develop Allogeneic T-Cell Therapies
PHILADELPHIA and OXFORD, United Kingdom, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, and Seattle-based Universal Cells Inc., a genome editing company developing universal donor stem cells, today announced that they have entered into a collaboration and exclusive license agreement for the development of allogeneic T-cell therapies. ... 
Printer Friendly Version
11/24/15Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer
OXFORD, United Kingdom and PHILADELPHIA, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of engineered T-cell therapy to treat cancer, today announced that it has initiated a study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with Stage IIIb or Stage IV non-small cell lung cancer (NSCLC), the most common type of lung cancer, representing approximately 85 percent of lung cancers. Adaptimmune is develo... 
Printer Friendly Version
11/13/15Adaptimmune Reports First Quarter Financial Results for Fiscal Year 2015-16
PHILADELPHIA and OXFORD, United Kingdom, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T-cell therapy to treat cancer, today reported financial results for the first quarter, which ended September 30, 2015. “The first quarter of our fiscal year was one of great progress for Adaptimmune as we made good headway toward our goal of delivering important T-cell therapy products to patients suffering from solid and hematologic cancers,” commen... 
Printer Friendly Version
11/12/15Adaptimmune to Participate in the Jefferies Autumn 2015 Global Healthcare Conference
PHILADELPHIA and OXFORD, United Kingdom, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the Jefferies Autumn 2015 Global Healthcare Conference at 11:20 AM GMT (6:20 AM EST) on Wednesday, November 18, 2015. The conference is being held at the Mayfair Hotel in London, UK. Adaptimmune’s presentation will be webcast live ... 
Printer Friendly Version
11/05/15Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)
PHILADELPHIA and OXFORD, UK, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today presents updated data on its lead clinical program, an affinity enhanced T-cell receptor therapy targeting the NY-ESO-1 cancer antigen in synovial sarcoma, at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC). Also being presented are an extended follow-up and correlative data from Adapt... 
Printer Friendly Version
10/30/15Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)
PHILADELPHIA and OXFORD, United Kingdom, Oct. 30, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present new data from trials of its NY-ESO affinity enhanced T-cell therapy in patients with synovial sarcoma and myeloma, as well as data from preclinical safety assessments of its affinity enhanced T-cell therapy directed at MAGE A-10, at the 2015 Ann... 
Printer Friendly Version
10/16/15Adaptimmune to Participate in the 2015 BIO Investor Forum
PHILADELPHIA and OXFORD, United Kingdom, Oct. 16, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that Helen Tayton-Martin, Chief Operating Officer of Adaptimmune will present at the 2015 BIO Investor Forum at 9:00 AM PDT (5:00 PM BST) on Tuesday October 20, 2015. The conference is being held at the Parc 55 Hotel in San Francisc... 
Printer Friendly Version
10/13/15Adaptimmune Reports Full Fiscal Year 2015 Financial Results
Conference Call to be Held Today at 8:00 AM ET (1:00 PM BST) PHILADELPHIA and OXFORD, United Kingdom, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today reported financial results for the full fiscal year 2015, which ended June 30, 2015. “This has been a period of exciting progress throughout our organization, marked by executio... 
Printer Friendly Version
10/09/15Adaptimmune Growth Leads to Long-Term Expansion Plans in Philadelphia
Company Selects The Navy Yard as Site for U.S. Headquarters and Base for Clinical and Manufacturing Operations PHILADELPHIA and OXFORD, UK, Oct. 09, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc. (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced plans to locate its U.S. headquarters and clinical operations in a newly developed facility to be constructed at The Navy Yard in P... 
Printer Friendly Version
10/07/15Adaptimmune to Report Full Fiscal Year 2015 Financial Results on October 13, 2015
PHILADELPHIA, Pa. and OXFORD, UK, Oct. 07, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, will announce financial results for its 2015 full fiscal year ended June 30 before the open of the U.S. markets on Tuesday, October 13, 2015.  Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. Eastern Time (1... 
Printer Friendly Version
10/06/15Adaptimmune Announces New Research and Development Facility in Oxfordshire
'Enterprise Zone' Building Will House Company's Expanding R&D Operation OXFORD, UK and PHILADELPHIA, Oct. 06, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced plans to expand its research and development operation into a major new purpose-built facility at Milton Park, Oxfordshire. Construction of Adaptimmune’s 67,000 squ... 
Printer Friendly Version
09/28/15Adaptimmune to Participate in the Leerink Partners Inaugural Immuno-Oncology Roundtable
PHILADELPHIA and OXFORD, UK, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), ("Adaptimmune" or the "Company"), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Chief Financial Officer of Adaptimmune, will present at the Leerink Partners Inaugural Immuno-Oncology Roundtable at 2:20 PM ET (7:20 PM BST) on Thursday, October 1, 2015. The conference is being held at the Le Parker Meri... 
Printer Friendly Version
09/14/15Adaptimmune to Participate in Two Upcoming Investor Conferences
PHILADELPHIA and OXFORD, UK, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), ("Adaptimmune" or the "Company"), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced participation in the following two investor conferences: James Noble, Chief Executive Officer of Adaptimmune, will present at the 2015 Morgan Stanley Global Healthcare Conference at 4:05 PM ET (9:05 PM BST) on Thursday, September 17, 2015. T... 
Printer Friendly Version
09/09/15Adaptimmune Announces Expansion of Senior Team to Augment Clinical Expertise and Support Growth
PHILADELPHIA and OXFORD, UK, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP) ("Adaptimmune" or the "Company"), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has added three new members of management to support the Company's growth and augment its clinical development expertise. Trupti Trivedi has joined as Vice President, Head of Biometrics, with responsibility for quantitative and com... 
Printer Friendly Version
09/03/15Adaptimmune to Participate in the 22nd Annual BioCentury 'NewsMakers in the Biotech Industry' Conference
PHILADELPHIA and OXFORD, UK, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), ("Adaptimmune" or the "Company"), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the 22nd Annual BioCentury 'NewsMakers in the Biotech Industry' Conference at 11:30 AM ET (4:30 PM BST) on Thursday, September 10, 2015. The conference is being held at the... 
Printer Friendly Version
09/01/15Adaptimmune Expands Trial of T-cell Therapy for Synovial Sarcoma and Achieves Clinical Milestones
First Patient Dosed in Expanded Phase I/II Study PHILADELPHIA, and OXFORD, UK, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), ("Adaptimmune" or the "Company"), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patient... 
Printer Friendly Version
08/04/15Adaptimmune to Participate in the Wedbush 2015 Life Sciences Conference
PHILADELPHIA and OXFORD, UK, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), ("Adaptimmune" or the "Company"), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Chief Financial Officer of Adaptimmune, will present at the Wedbush 2015 Life Sciences Conference at 9:45 AM ET (2:45 PM BST) on Tuesday, August 11, 2015. The conference is being held in New York City. Adaptimmune's pres... 
Printer Friendly Version
07/20/15Adaptimmune's NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence, Clinical Activity and Tolerability in Clinical Study in Multiple Myeloma Patients
Data Published in Nature Medicine PHILADELPHIA and OXFORD, England, July 20, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine. The paper entitled NY-ESO-1 Specif... 
Printer Friendly Version
07/02/15Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients With Non-Small Cell Lung Cancer
PHILADELPHIA and OXFORD, England, July 2, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors (TCRs) specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced ... 
Printer Friendly Version
05/30/15Adaptimmune Announces Data From Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting
OXFORD, England and PHILADELPHIA, May 30, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers. Eighty-two (82) patients have been treated to date with NY-ESO-T; 44... 
Printer Friendly Version
05/21/15Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting
OXFORD, England and PHILADELPHIA, May 21, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting. These data pertain to clinical results from myeloma, s... 
Printer Friendly Version
05/20/15Adaptimmune Announces New Additions to Senior Clinical Management
OXFORD, UK and PHILADELPHIA, May 20, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has augmented its senior management team with the additions of Lini Pandite, M.D. as Senior Vice President, Clinical Development, and Anne-Marie (Annie) Martin, Ph.D. as Vice President, Head of Biomarker Research and Development. Dr. Pandite will be responsible for global clinical deve... 
Printer Friendly Version
05/13/15Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting
OXFORD, UK and PHILADELPHIA, May 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data at the 18th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The data in this presentation pertain to the phenotypic and functional evaluation of  engineered T-cells targeting NY-ESO-1 in the blood of patients following infusion in Phase ... 
Printer Friendly Version
05/12/15Adaptimmune Announces Appointment of Vice President of Investor Relations
OXFORD, UK and PHILADELPHIA, May 12, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has strengthened its senior management team with the appointment of William (Will) Roberts as Vice President, Investor Relations. Mr. Roberts will lead the company's investor communications strategies, along with involvement in wider communication programs and activities. Mr. Rober... 
Printer Friendly Version
05/11/15Adaptimmune Announces Closing of Initial Public Offering
OXFORD, UK and PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP) today announced the closing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. The aggregate net proceeds to Adaptimmune, after underwriting discounts and commissions and estimated offering expenses, were approximately $175.7 million. As previously reported, Adaptimmune has granted the underwriters a 30-day option to purchase up to an add... 
Printer Friendly Version
05/06/15Adaptimmune Announces Pricing of Initial Public Offering
OXFORD, United Kingdom and PHILADELPHIA, May 6, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced the pricing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,687,500 ADSs. The ADSs are expected to begin trading on the NASDAQ Global Select Market under the symbol "ADAP" on May 6, 2015.&nb... 
Printer Friendly Version
03/10/15Adaptimmune appoints Lawrence M. Alleva to its Board of Directors
Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, today announces the appointment of Lawrence (Larry) M. Alleva, to its Board of Directors as an independent, non-executive director with immediate effect. Mr. Alleva will also serve as chairman of the Board Audit Committee. Please click on the link below to download the full Press Release:- Adaptimmune appoints Lawrence M. Alleva to its Board of Directors... 
Printer Friendly Version
03/04/15Adaptimmune Strengthens Management Team with Key Executive Hires
Adaptimmune today announces that it has strengthened its senior management team with the appointment of Dr. Rafael Amado, as Chief Medical Officer, and Adrian (Ad) Rawcliffe, as Chief Financial Officer. Both appointments are effective from 16 March. Please click on the link below to download the full Press Release:- Adaptimmune Strengthens Management Team with Key Executive Hires... 
Printer Friendly Version